Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Fulvestrant Plus Capivasertib Versus Placebo After Relapse or Progression on an Aromatase Inhibitor in Metastatic, Oestrogen Receptor-Positive Breast Cancer (FAKTION): A Multicentre, Randomised, Controlled, Phase 2 TrialLancet Oncol 2020 Feb 05;[EPub Ahead of Print], RH Jones, A Casbard, M Carucci, C Cox, R Butler, F Alchami, TA Madden, C Bale, P Bezecny, J Joffe, S Moon, C Twelves, R Venkitaraman, S Waters, A Foxley, SJ Howell
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.